Introduction {#sec0001}
============

In December 2019, an unprecedented number of pneumonia cases presented in adult individuals from Wuhan, China [@bib0001]. Despite rapid action by the Chinese government and health officials, the number of similar presenting cases continued to rise at an alarming rate [@bib0002]. By January 2020 an emerging zoonotic agent, known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), was identified in respiratory samples in patients diagnosed with pneumonia who subsequently developed respiratory failure [@bib0001]. The spread of SARS-CoV-2 from human to human, through respiratory droplets, has now resulted in a worldwide outbreak, now classified as a pandemic by the World Health Organization [@bib0003].

As of June 3rd, 2020, there has been more than 6·4 million confirmed cases worldwide and \>380,000 fatalities [@bib0004] Most symptomatic cases have occurred in the adult population, characterized by fever, cough, malaise, and frequent hospitalization \[[@bib0001]\]. Accordingly, most of the published data is derived from adults with coronavirus disease 2019 (COVID-19) who were hospitalized in China [@bib0005]. As the pandemic continues, we are now observing numerous reports describing the clinical presentation and hospital course of children with confirmed COVID-19 [@bib0005].

What is currently known is that children have milder symptoms and are less likely to be hospitalized when compared to adults [@bib0006]. However, on May 14th, 2020 the United States Centers for Disease Control and Prevention (CDC) released a health advisory reporting a multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 [@bib0007]. This statement stemmed from a subset of pediatric patients manifesting with severe inflammation, multi-organ failure, and testing positive for SARS-CoV-2 \[[@bib0008],[@bib0009]\].

Our goal was to conduct a systematic review: (i) to understand the clinical picture and presentation of pediatric patients with confirmed COVID-19, and (ii) to provide an initial observation of the signs, symptoms, and laboratory findings of pediatric patients who developed MIS-C.

Methods {#sec0002}
=======

2.1 Search strategy and selection criteria {#sec0003}
------------------------------------------

Our methods adhere to the guidelines established by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Our study protocol was registered with PROSPERO (International Prospective Register of Systematic Reviews) under the following identifier \# CRD42020182261*.*

We conducted a systematic search in the following databases: PubMed, LitCovid, Scopus, and the WHO COVID-19 database. Additionally, we searched for studies that included the following terms- "novel coronavirus, COVID-19, 2019-nCOV, SARS-CoV-2, pediatric, child, and neonate" into the freely accessible research domains of JAMA, Lancet, NEJM, CHEST, and Google Scholar. The last search was performed on May 14th, 2020 and was not limited by language (translation performed with Google Translate).

We included published or in press peer-reviewed articles reporting pediatric cases of confirmed COVID-19. We accepted the following types of studies: cross-sectional, cases series, case-control, case reports, review articles, opinion papers, and letters to journal editors that incorporated clinical, laboratory, imaging, and hospital course of pediatric patients. The pediatric population included neonates, children, and young adults up to 21 years of age. We set the upper limit of age to 21 years as several countries use this number to stratify their pediatric versus adult data. Patients were included if SARS-CoV-2 was detected by real time reverse transcription polymerase chain reaction (RT-PCR) in nasopharyngeal, throat, blood, or stool samples at any point of their clinical evaluation. Suspected cases of COVID-19 without positive RT-PCR were excluded in this study. Furthermore, we also excluded *in vitro* studies or manuscripts focusing on animal experiments.

Screening by title and abstract was conducted independently by at least two investigators (AH, KC, or AxM). A third investigator (AM) was consulted to resolve differences of opinion in either phase. Subsequent full-text review and data extraction was conducted by all investigators using a standardized online form shared among the authors. Data retrieved from each article was cross-checked by at least two independent investigators.

Our outcomes of interest were to describe the clinical signs, imaging findings, and laboratory results characteristic of pediatric patients with confirmed COVID-19. Also, we wanted to provide an initial description of children with confirmed diagnosis of SARS-CoV-2 who develop MIS-C. We used the definition by the CDC to define MIS-C

(e.g., fever, laboratory evidence of inflammation, and evidence of clinically severe illness requiring hospitalization, with multisystem (≥2) organ involvement with no alternative diagnosis, and positive for SARS-CoV-2 infection) [@bib0007]. Control cases were patients from the same case series who did not meet criteria for MIS-C or studies that presented individual patient data where MIS-C could be definitively ruled out.

2.2 Data collection and risk of bias assessment {#sec0004}
-----------------------------------------------

Data extraction was performed by all investigators and compared by at least two investigators for consistency. Data collected included the type of article (e.g., case series), country of origin, number of pediatric patients, demographic information, and all clinical symptoms (e.g., fever, cough), laboratory values (e.g., CBC, LFTs, BMP), imaging studies (e.g., chest x-ray, CT, MRI), clinical outcomes (e.g., ICU admission), and treatments provided (e.g. antivirals).

The risk of bias for observational studies was appraised through the quality assessment tool published by the National Institutes of Health [@bib0010]. We opted to use this guide as the development of the assessment tool was conducted rigorously by researchers in the Agency for Healthcare Research and Quality Evidence-Based Practice Centers, the Cochrane Collaboration, the United States Preventive Services Task Force, the Scottish Intercollegiate Guidelines Network, the National Health Service Centre for Reviews and Disseminations, and consulting epidemiologists. Moreover, it was a preferred tool in a systematic review on risk of bias assessments used in PROSPERO-registered protocols [@bib0011]. Risk of bias was assessed independently by at least two investigators and disagreements were resolved by a third researcher (AM). Furthermore, the level of evidence was assessed according to Sackett [@bib0012].

2.3 Data analysis {#sec0005}
-----------------

All laboratory data were converted to similar units and presented as mean with standard deviation (SD). Laboratory information presented as median (IQR) were converted to mean (SD), and denoted when unable to convert [@bib0013]. Publications that provided multiple timepoints (e.g., hospital course of individuals) for laboratory results were gathered and averaged. If the symptom was present anytime during the hospitalization, it was considered positive and characterized as a count with percent. A similar approach was taken for imaging information. Means, standard deviations, and proportion ratios were calculated using Microsoft Excel.

Statistical analyses between COVID-19 pediatric patients with/without MIS-C was conducted on STATA v·13. All statistical tests were two-sided, and significance was defined as a p value \<0·05. Continuous data was summarized as mean (standard deviation) or median (interquartile range) and assessed by Student\'s t-test or Wilcoxon rank sum. Categorical data was summarized as counts (percent) and analyzed by Fisher\'s exact test.

2.4 Role of the funding source {#sec0006}
------------------------------

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results {#sec0007}
=======

The search yielded 1,142 studies. After removing 237 duplicates, 905 articles were reviewed by abstract and title. After initial screening, only 319 articles met inclusion criteria and underwent full text evaluation. Publications that were retracted, or consisted of editorials, reviews, or commentaries that did not meet our criteria were removed, generating a final list of 131 articles (see [Fig. 1](#fig0001){ref-type="fig"}).Fig. 1PRISMA flow diagram.Fig 1

Studies included in this review were published between January 24th to May 11th, 2020. Eight studies were cross sectional, 75 were case series, and 48 were case reports (refer to [Table 1](#tbl0001){ref-type="table"}). Twenty-six countries were represented with the largest data derived from 2572 children from the United States. China comprised 64·1% of the studies included in this review. Appendix 1 displays publications by the country of origin.Table 1Study characteristics.Table 1**\#First authorStudy typeCountryNAge (years)Male NClinical symptomsLaboratory findingsImaging characteristicsTherapyICU (N)**1\
Aghdam, MCase reportIran10.0421 (100%)Fever, lethargy, mottling, respiratory distressNormal CBC, BUN, Cr, and ABGNormal CXR, no lung CTFluids, oxygen, antibiotics, oseltamivir12Almeida, FCase reportBrazil1100\
(0%)Fever, cough, sore throat, gross hematuriaUrinalysis showed normal shaped red cellsNRNR03Alonso Diaz, CCase reportSpain10.0220\
(0%)Tachypnea, retractions, and desaturations 9 days after birthNormal CRP and capillary gasCXR: ground glass opacities in the right perihilar regionObservation14An, PCase reportChina130\
(0%)AsymptomaticNRCT: bilateral consolidation and ground-glass opacitiesAntibiotic05Andina, DCase series\*Spain1NR0\
(0%)Mild gastrointestinal symptoms and chilblains on feetNRNROral analgesic, antihistamine, topical corticosteroids for some patientsNR6Andre, NCase seriesFrance59.62\
(40%)Respiratory compromise in children with oncologic diseaseNRNRNR57Bi, QCase seriesChina32NRNRTime to recovery better in children \<9 years of age (17.5 days) vs. 10-19 years (19.1 days), secondary household attack rate \~7.25%NRNRNRNR8Cai, JCase seriesChina106.174\
(40%)7 patients with fever, 6 with cough, 4 with sore throat, 0 with diarrhea, all patients were symptomatic↑CRP (n=8), ↑PCT (n=6), ↑LDH (n=3); ↑WBC (n=3), ↑D-dimer (n=2)CXR: unilateral patchy infiltrates (n=4)Symptomatic treatment (n=5), symptomatic treatment + antibiotics (n=5)09Cai, JHCase reportChina171\
(100%)Fever, cough, rhinorrhea, nausea↑WBC, CRP, and D-dimerCXR: Bilateral thickening of lung textureObservation, Chinese medications010Calvo, CCross sectionalSpain52.50\
(0%)NRNRNRNRNR11Canarutto, DCase reportItaly10.0881\
(100%)Fever, cough, and rhinorrheaMild neutropenia, monocytosis, and reactive lymphocytes on blood smearCXR:normalNRNR12Carrabba, GCase reportItaly10.671\
(100%)Mild temperature, dry coughNRCXR:no overt interstitial pneumonia but mild veiling opacity of left lung, no lung CTNeurosurgery for shunt revision x2013CDC COVID 19 Response teamCase seriesUSA25729.81408 (57%)Symptom data available for 291 patients: 56% of pediatric patients reported fever, 54% reported cough, and 13% reported shortness of breath, 53 of 78 cases did not report symptoms, 23% (n=80) of 345 patients had at least 1 underlying medical condition, 3 deathsNRNRNR1514Cela, ECase seriesSpain1510.114\
(93%)Fever (n=10), cough (n=6), asymptomatic (n=2), hypoxemia (n=2), all patients with oncologic diseasemedian WBC 3.2, median lymphocyte 18.2%, median D-dimer normalCXR: normal (n=6), pneumonia (n=4), peribronchial cuffing (n=4)Hydroxychloroquine (n=11), tocilizumab & lopinavir/ritonavir (n=1), oxygen (n=2), antibiotic (n=2), remdesivir (n=1), no treatment (n=4)NR15Chacon-Aguilar, RCase reportSpain10.071\
(100%)Paroxysmal episodes with generalized hypertonia, fever, rhinorrhea, vomiting, diarrheaCBC, liver and kidney studies normal, ↑CK (380 U/L), ↑LDH (390 U/L), normal CRPNRAntibiotics016Chan, JFCase series\*China1101\
(100%)AsymptomaticNormal CBC, fibrinogen, CRP, Cr, LDH, and CK, ↑alkaline phosphataseCT: bilateral ground-glass opacitiesNR017Chang, DCase seriesChina28.5NRFever, coughNRNRNR018Chen, FCase reportChina11.081\
(100%)Fever, shortness of breath, vomiting, diarrhea, myalgia/fatigue, cold limbs with poor perfusionNormal ABG, coagulation profile; LFTs, ↑BUN, Cr, CK, serum amyloid, IL-6, IL-10CXR: large blurred image of the upper and lower right lung; CT: enhanced texture of both lungs, large consolidation on the right, ground-glass shadowContinuous dopamine, IV bolus, ventilator assistance, correction of acidosis, interferon, glucocorticoid, oseltamivir, antibiotics, abdominal decompression119Chen, HCase reportChina1121\
(100%)Fever, cough, abdominal pain, sputum production, no vomitingNormal CBC, ↑CRPCT: pneumonia in the right upper lung, followed by bilateral ground-glass opacitiesAntibiotics, arbidol, and supplemental oxygenNR20Chen, JCase seriesChina1214.56\
(50%)Cough (75%), fever (58.3%), diarrhea (33%), dizziness (16.7%), sore throat (16.7%)Normal CBC, LFTs, BUN, PT, ↑total B and T cells when compared to adults, but comparable NK cell, IgM, IgG, and C3Ground-glass opacity was the most common finding on chest CTAll patients received interferon, 8 received lopinavir/ritonavir, and 2 received ribavirin021Cui, YCase reportChina10.150\
(0%)Pharyngeal hyperemia, rhinorrhea, cough, sputumSlightly elevated IgM, lymphocyte, and platelet counts; normal Hgb, D-dimer, PTT, PT, CRP, ESR, and renal functionCT: Unilateral ground-glass opacity in the right lung and unilateral consolidationInterferon, antibiotic, ursodeoxycholic acid, Chinese medicine122de Rojas, TCase seriesSpain1510.114\
(93%)10 patients had fever, 6 patients had cough, 1 with hypoxemia, and 2 asymptomatic patients; all patients had an underlying oncologic diseaseMedian WBC count was 3,195 and median lymphocyte count was 580CXR: normal (n=6), pneumonia (n=4), peribronchial cuffing (n=4)11 patients received hydroxychloroquine and 2 received antibiotics, tocilizumab (n=1), lopinavir-ritonavir (n=1), glucocorticoid (n=1), and remdesivir (n=1)023Denina, MCase seriesItaly84.25\
(63%)Fever (n=6), dry cough (n=5), dyspnea (n=3), pharyngeal congestion (n=3), vomiting or diarrhea (n=3), hypoxemia (n=2)NRCXR: pulmonary consolidation (n=1), ground-glass opacities (n=4); LUS: confluent B-lines (n=5), subpleural consolidations (n=2)Oxygen (n=2)NR24Dona, DCase seriesItaly20.29NRFever (n=1) diarrhea (n=1), respiratory symptoms in bothNRNRNR025Dong, LCase reportChina10.0030\
(0%)AsymptomaticNasopharyngeal test was negative, but IgM and IgG were elevated 2 hours after birth, ↑IL-6, IL-10, LDHCT: normalNR126Dong, YCase seriesChina73110420\
(58%)315 mild illness, 300 moderate illness, 18 severe and 3 critically ill, 94 asymptomatic childrenNRNRNRNR27Du, WCase seriesChina147.16\
(43%)Fever (n=5) and cough (n=3) were commonly reported; Eight (57.1%) were asymptomatic↑LDH (n=7), ↑PCT (n=5), ↑D-dimer (n=5), ↑CK (n=4), leukopenia (n=4), ↑IL-6 (n=1)CT: bilateral lung injury (n=6) and unilateral (n=5)NR028Fan, QCase reportChina10.250\
(0%)Fever and diarrheaNeutrophilia (86.2%), lymphopenia (7.1%)CT: normalSupportive care029Feng, KCase seriesChina1574\
(33%)Asymptomatic (n=8), fever (n=5), cough or nasal congestion (n=1)↓WBC (n=8), normal WBC (n=7)CT: ground glass lesions (n=7), no lesions (n=6), patchy shadow (n=2)NRNR30Ferrazzi, ECase seriesItaly30.003NR1 neonate with gastrointestinal and respiratory symptoms 3 days after birthNRNRNR131Genovese, GCase reportItaly180\
(0%)Fever, cough, papulovesicular rash to trunkNormal complete blood count, CRP, liver and kidney function, mild thrombocytopenia (105k)NRNRNR32Guan, WCase seriesChina9NRNRNRNRNRNRNR33Gubjartsson, DCross sectionalIceland1321NRNRNRNRNRNRNR34Han, MCase reportKorea10.070\
(0%)Fever, cough, and vomiting; viral shedding in urine and stool for 10 and 18 days, respectivelyFirst CBC with mild neutropenia (817 per mm3)CXR: normalNo antibiotics or antivirals035Han, YCase seriesChina744\
(57%)Fever (n=5), cough (n=5), shortness of breath (n=3), vomiting (n=4), diarrhea (n=4), sore throat (n=1), myalgia (n=1)↑BNP (n=5), ↑CK (n=4), ↑PCT (n=3), ↑AST (n=3), ↑LDH (n=2), ↑CRP (n=2)Pneumonia on CT and CXR (n=5)Oxygen therapy (n=2) glucocorticoids (n=1)036Hrusak, OCross sectionalCzech Republic, USA, Italy, Spain, Switzerland, Denmark, Austria, Sweden, Belgium, Netherlands9NRNRFever (n=7) and diarrhea (n=1) were the most common symptoms in this cohort of children with oncologic diseaseLymphopenia (n = 1), neutropenia (n=5)Normal CXR in 1 patient, all others NRAntibiotics (n=2) lopinavir/ritonavir (n=1) hydroxychloroquine (n=2)037Hu, XCase series\*China10.0041\
(100%)AsymptomaticWBC, Hgb, Plts, CRP, Cr, ALT normal, ↑PCT (n=6)Normal CXR=1; no CT dataNR038Ibrahim, LCase seriesAustralia413.11\
(25%)Sore throat (n=4), headache/dizziness (n=3), cough (n=2), fever (n=1)NRNRNone039Ji, LCase seriesChina2122\
(100%)Fever and diarrhea (n=1)↑WBC (n=1), ↑CRP (n=1)CT: normal (n=2)Symptomatic treatment, oral probiotic040Ji, TCase seriesChina19NRNRAsymptomatic (n=9)NRNRNRNR41Jiang, SCase seriesChina25.080\
(0%)Fever, cough, and vomiting in both patients↑WBC, neutrophil count, CRP, PCT, serum amyloid A (n=1)CT: normal (n=1), bilateral ground-glass opacities with patchy shadows (n=1)Antibiotics (n=2), oseltamivir (n=1), glucocorticoids (n=1), IVIG (n=1)142Jones, VCase reportUSA10.50\
(0%)Fussy, conjunctivitis, dry cracked lips, prominent tongue papilla, polymorphous maculopapular rash, swelling of hands and feet, fever, anorexiaWBC with bandemia, ↑CRP, normal ESR, BMP, and LFTsCXR: faint opacity in left midlungIVIG and acetylsalicylic acidNR43Kam, KCase reportSingapore10.51\
(100%)Asymptomatic initially, followed by feverViremia, normal CBC, LFTsNRNRNR44Kan, MCase reportUSA10.020\
(0%)Fever, tachycardia, cough; underlying condition of hydronephrosis and duplicating renal systemLeukopenia, lymphopenia, neutropenia, normocytic anemia, normal platelets, normal CRPNRBolus, antibiotic, antipyretics045Korean Society of Infectious DiseasesCross sectionalKorea201NRNRNRNRNRNRNR46Lai, WCase seriesChina2142\
(100%)2 with dry cough, 2 with fever, and 1 with malaiseNRCT: unilateral patchy ground-glass opacities (n=2)Antivirals, supportive047Le, HCase reportVietnam10.250\
(0%)Rhinorrhea and nasal congestion, fussyNormal CBC, CK, LDH, CRP, and PCTCXR:normalAntibioticNR48Leva, ECase seriesItaly16NRNRAll patients with fever and coughNRNRNR449Li, HCase seriesChina405.123\
(58%)Cough (n=27), fever (n=21), myalgia (n=4), diarrhea (n=4), rhinorrhea (n=2), sore throat (n=2)Normal CBC, CRP, PCT, ↑CD3^+^, CD8^+^ lymphocyte (n=40), ↑% of CD3^+^ (n=40), and ↓ percentage of CD19^+^ lymphocyte (n=40)CT: unilateral (n=13), bilateral (n=26) ground-glass opacities, normal (n=1)Interferon (n=40), oseltamivir (n=20), IVIG (n=4), steroids (n=3), azithromycin (n=13), mechanical ventilation (n=1)150Li, JCase reportChina10.670\
(0%)CoughWBC and differential, PT, D-dimer, LFTs and renal function normal, ↑CRPNormal CTInterferon051Li, MCase reportChina10.0061\
(100%)Patient had no fever or coughNRNRNR052Li, WCase seriesChina47.24\
(100%)CoughNRNRNRNR53Li, WeiCase seriesChina53.44\
(80%)Asymptomatic (n=4), 1 patient with rhinorrhea, cough, sore throat, and fever↑WBC (n=2), ↑CRP (n=1)CT: patchy ground-glass opacities (n=3), normal (n=2)IVIG (n=5), antivirals (n=2), montelukast (n=3), interferon (n=2)NR54Li, YCase seriesChina241\
(50%)Cough and rhinorrhea (n=1)↓neutrophils (n=1), ↑CRP (n=1), normal coagulation profile, LFTs and renal function in both patientsCT: bilateral spots upper lobes (n=1), increased bronchovascular bundles bilaterally (n=1)Oxygen (n=1)055Lin, JCase reportChina170\
(0%)Nasal congestion and dry cough; no fever, dyspnea, or diarrheaNRCT showed no signs of pneumoniaSupportive treatment, oseltamivir, and interferonNR56Liu, MCase seriesChina56.44\
(80%)3 were asymptomatic, 2 patients with fever and dry coughNormal WBC, mild neutropenia (n=3)CT: unilateral (n=3) and bilateral (n=1) ground-glass opacitiesInterferon (n=4), ribavirin (n=3)NR57Liu, WCase seriesChina63.52\
(33%)High fever and cough in all patients; vomiting (n=4)White cells (n=4), lymphocytes (n=6), and neutrophils (n=3) were decreasedCT: patchy shadows bilaterally (n=3), patchy ground-glass opacities in both lungs (n=1), normal (n=1)Oseltamivir (n=6), glucocorticoid (n=4), ribavirin (n=2), IVIG (n=1)158Liu, YCase reportChina1101\
(100%)AsymptomaticNormal CBC, LFTs, ↑LDH, borderline ↑CRPCT: ground-glass opacity and pleural effusionRibavirin, interferon059Locatelli, ACase reportItaly1161\
(100%)Mild diarrhea and chilblain-like lesions to fingers and a toeCoagulation, autoimmunity, cryoglobulins normalNRNRNR60Lou, XCase seriesChina34.81\
(33%)All patients had fever; 2 with fatigue, nasal congestion, diarrhea, and headacheNRNRInterferon (n=2)061Lu, XCase seriesChina1716.4104\
(61%)Fever (41.5%), pharyngeal erythema (46.2%), diarrhea (8.8%), asymptomatic (15.8%), 1 death↓WBC (26.3%), lymphopenia (3.5%), ↑PCT (64%), ↑CRP (19.7%), ↑D-dimer (14.1%), ↑AST (14.6%)CT: ground glass opacity (32.7%), unilateral or bilateral patchy shadowing (31%), interstitial abnormalities (1.2%)NR362Lu, YCase seriesChina97.85\
(56%)Fever (n=6), cough (n=3), asymptomatic (n=1)All WBC counts were normalCXR: no overt abnormality (n=5); CT: no overt abnormality (n=4), patch ground-glass opacities (n=4)NR063Lu, YingyingCase seriesChina1105.859\
(53%)Cough and dyspnea (51.8%), followed by fever (50.9%) were the most common symptoms, 26 (23.6%) patients had gastrointestinal symptoms, 29 (26.4%) were asymptomaticSymptomatic patients were more likely to have a ↓Hgb (16.4% vs. 0%), ↑AST (23.5% vs. 0%), and trended towards an ↑IL-6 (12% vs. 0%)64 patients had a chest x-ray demonstrating pneumoniaAll received antivirals, interferon was the most frequently used, Chinese medication (n=22)064Ma, HCase seriesChina503.328\
(56%)32 with fever, 22 with cough, 8 with rhinorrhea, 1 with sore throat, 2 with myalgia, 3 with diarrhea, 6 with no symptomsLeukocytosis (n=2), leukopenia (n=19), polycythemia (n=2), thrombocytopenia (n=7), ↑CRP (n=10)CT: ground-glass opacities (n=29), local patchy shadowing (n=9), normal (n=7)NRNR65Ma, H~2~Case seriesChina225.512\
(55%)Fever (n=13), dry cough (n=5), shortness of breath (n=1), asymptomatic (n=2)NRCT: ground-glass shadows (n=6), consolidation (n=4), consolidation and ground-glass shadows (n=6), bronchial pneumonia-like changes (n=3), normal (n=3)NRNR66Ma, YCase seriesChina115NR73\
(64%)Asymptomatic (n=61), fever (n=29), cough (n=47), rhinorrhea (n=47), gastrointestinal symptoms (n=3)Normal WBC (n=88), ↓WBC (n=23); lymphocytes normal (n=60), ↑lymphocytes (n=40); normal neutrophils (n=77),↑neutrophils (n=32), ↑ALT (n=11), ↑CK-MB (n=34), ↑BUN/Cr (n=2)CT: ground-glass opacities (n=49), normal (n=27)NRNR67Mansour, ACase reportLebanon11.330\
(0%)Patient presented with fever, diarrhea, and decreased activityLeukocytosis, elevated platelets, elevated CRP, decreased hemoglobin/hematocritCXR: unilateral, large consolidation with bronchial infiltrateHydration and antibiotics068Mao, LCase reportChina11.161\
(100%)Patient presented with fever, cough, congestion, rhinorrhea, decreased appetiteNormal CBC, PCT, LFTs, renal function, D-dimer; normal T cell, B cell, and NK cell, ↑CRPCT: unilateral ground-glass opacities in right lower lungInterferon and supportive069Mizumoto, KCase seriesJapan3NRNRAsymptomatic (n=2)NRNRNRNR70Morey-Olive, MCase seriesSpain231\
(50%)Low grade fever (n=2)Abnormal liver enzymes and coagulation parameters in 1 patientNRNR071Munoz, ACase reportUSA10.061\
(100%)Nasal congestion, tachypnea, reduced feeding, subsequent pneumothorax↑PCT (6.53 ng/mL) and ↑CRP (172 mg/L)CXR: bilateral linear opacities and consolidation of right upper lobeMechanical ventilation, antibiotics, hydroxychloroquine, vasopressors172Nathan, NCase seriesFrance50.185\
(100%)All had fever, 4 patients with hypotonia or drowsiness and moaning, 4 with cough and rhinorrheaCBC normal, ↑CRP (n=3), ↑PCT (n=1)Normal CXR in 4 patients, 1 patient with hyperinflationAntipyretics073Ng, KCase seriesUK80.392\
(25%)Fever (n=5), anorexia (n=4), tachypnea (n=2), skin mottling (n=1)2 patients had neutropenia and thrombocytosis2 patients had some opacities on CXR4 patients treated with broad-spectrum antibiotics274Odievre, MCase reportFrance1160\
(0%)Fever, followed by acute chest syndrome in a patient with sickle cell disease↑CRP, ↑D-dimer, ↑IL-6, ↑LDH, ↑TNF-αCT: bilateral pulmonary embolisms and bilateral consolidation with halo sign on rightAcetaminophen, non-invasive ventilation, blood transfusion, anticoagulation, tocilizumab175Pan, ACase seriesChina536NRNRNRNRNRNRNR76Park, JCase reportKorea1100\
(0%)Low-grade fever and sputum productionCBC, CRP normal, stool sample remained positive for 17 days after symptom onsetCT: unilateral patchy or nodular consolidations with peripheral ground-glass opacitiesNone077Parri, NCase seriesItaly100657\
(57%)Fever (n=54), cough (n=44), rhinorrhea (n=22), asymptomatic (n=21), shortness of breath (n=11), nausea (n=10), vomiting (n=10), diarrhea (n=9), myalgia (n=9), sore throat (n=4), headache (n=4); 27 patients with underlying medical conditionsWBC normal (n=40), ↓WBC (n=11), lymphocytopenia (n=14), ↑PCT (n=4), ↑LDH (n=22), ↑ALT (n=8), ↑AST (n=10)CXR: interstitial abnormality (n=14), normal (n=15), consolidation (n=6), pleural effusion (n=1); LUS: interstitial syndrome (n=9), small sub-pleural consolidations (n=4)Non-invasive ventilation; mechanical ventilation (n=1)978Patek, PCase reportUSA10.041\
(100%)Fever, hypoxemiaNormal CBC, mild elevation to AST and ALT, CSF unremarkableCXR: bilateral perihilar streaking without focal consolidationOxygen, empiric antibiotics, acyclovir179Patel, PCase reportUSA1120\
(0%)Fever, cough, vomiting, hematuria, and respiratory failureSevere thrombocytopenia (\<10k per μL), elevated inflammatory markers (CRP, PCT, ferritin)CXR: bilateral diffuse airspace opacities and small pleural effusion\
IVIG, corticosteroids, mechanical ventilation, nitric oxide, azithromycin,hydroxychloroquine, tocilizumab180Piersigilli, FCase reportBelgium10.0020\
(0%)No COVID-related symptoms; child is an extremely premature neonate↓WBC and lymphopeniaNormal radiographic findingsContinuous positive airway pressure181Qian, GCase series\*China11.080\
(0%)AsymptomaticNRCT: normalNR082Qiu, HCase seriesChina368.323\
(64%)Fever (n=13), cough (n=7), headache (n=3), vomiting/diarrhea (n=2)Leukopenia (n=7), ↓lymphocytes (n=11), ↑PCT (n=6), ↑CK-MB (n=11)CXR: ground-glass opacities (n=19)Interferon (n=36), lopinavir/ritonavir (n=14), oxygen (n=6)NR83Qiu, LCase reportChina10.661\
(100%)Fever, cough, wheezing, apnea, mottled skin, petechiae, cold fingers; patient with cardiac historyInitial labs demonstrated lymphopenia, ↓CD3+, ↓CD4+, ↓CD8+, ↓fibrinogen, ↑LDH, normal PCT and renal functionCXR: increased density, profusion, thickened lung texture; CT: multiple ground-glass opacities and patchy, high density shadowsIVIG, lopinavir/ritonavir, methylprednisolone, fluids, electrolytes, pressors184Robbins, ECase reportUSA10.161\
(100%)FeverCBC within normal limits, CMP normal except for a mildly elevated alkaline phosphatase and calciumCXR: normalAntibiotics, supportiveNR85Schwierzeck, VCase seriesGermany310NRAsymptomatic (n=2), fever (n=1), cough (n=1), nasal congestion (n=1) in patients with renal diseaseNRNRNRNR86See, KCase seriesMalaysia46.43\
(75%)Mild fever and diarrhea (n=1); rhinorrhea (n=1), cough and fever (n=1 mild), asymptomatic (n=1)NRCXR: perihilar opacities (n=2)Antipyretics (n=2), antibiotic (n=1), rehydration (n=1), salbutamol (n=1)087Shekerdemian, LCross sectionalUSA, Canada4811.325\
(52%)11 patients (23%) with multi-organ failure, 73% (n=35) with pulmonary symptoms, 40% (n=19) of children were medically complexNRNRNo medications (n=20), hydroxychloroquine (n=21), 17% underwent antiviral therapy, tocilizumab (n=5), mechanical ventilation (n=18), azithromycin (n=8)\
88Shen, QCase seriesChina97.53\
(33%)2 asymptomatic, 3 with fever, 1 with diarrhea, sore throat, or cough, and 1 with fever and diarrhea↑WBC (n=1), ↑lymphocyte count (n=1), ↑CRP (n=1), ↑ESR (n=4), ↑LDH (n=4)Normal chest x-ray and lung CT in 7 patients, 2 (22.2%) with small ground-glass opacitiesAll received oxygen and lopinavir/ritonavir, antibiotic treatment for 5 children, glucocorticoids and IVIG for 1 patient089Shi, BCase reportChina10.231\
(100%)Cough, wheeze, dyspneaWBC normal, ↑lymphocyte and platelet count; IgG, IgM, IgA, T, B, and NK cells normal, LFTs normal, RSV+CT: left lower lobe consolidationAntibiotics, CPAP, IVIG, corticosteroids, interferon, Chinese medication190Shi, YCross sectionalChina1065\
(50%)NRNRNRNR091Sieni, ECase reportItaly11.080\
(0%)Fever, vomiting, and diarrhea; patient with underlying oncologic diseaseLeukopenia, anemia, thrombocytopeniaCXR: bilateral reticular findingsAntifungal, antibiotics, hydroxychloroquine, lopinavir/ritonavir092Sinelli, MTCase reportItaly10.0061\
(100%)Hypoxemia, perioral cyanosis, poor suckingNormal complete blood count and C-reactive proteinCT: mild bilateral ground-glass opacitiesOxygen support193Song, RCase seriesChina73.51\
(14%)Most asymptomatic, only 2 had feverNormal WBC, ↓neutrophils, ↑LDH, normal fibrinogenNRAll patients received supportive care, interferon, lopinavir/ritonavirNR94Song, WCase seriesChina167.910\
(63%)Asymptomatic (n=8), cough (n=6), fever (n=5)Leukocytes normal (n=14), CRP normal (n=15), liver, renal, coagulation, electrolytes, and myocardial labs were normal, ↑LDH (n=3)CT: normal (n=5), bilateral ground-glass opacities (n=8), bilateral consolidation (n=1), patchy/nodular shadow (n=3)Oseltamivir (n=11), antibiotics (n=9), lopinavir/ritonavir (n=4), Chinese medicine (n=13), arbidol (n=6)095Su, LCase seriesChina93.53\
(33%)Asymptomatic (n=6), fever or cough (n=3)↑CK-MB (n=6), ↓WBC (n=2), LFTs normal, inflammatory markers (CRP, PCT, ESR, IL-6) were normal in all patients, stools positive in 5 children warranting readmissionCT/x-ray: normal (n=5), bronchitis (n=2), pulmonary consolidation and ground-glass opacities (n=1), bronchopneumonia (n=1)Interferon given to all patients; ribavirin (n=1)096Sun, DCase seriesChina86.66\
(75%)Tachypnea (n=8), fever or cough (n=6 each), sputum production (n=4), nausea/vomiting (n=4), diarrhea (n=3), fatigue or headache (n=1 each)Normal/↑ WBC (n=7), ↑CRP, ↑PCT, ↑LDH (n=6), abnormal LFTs (n=4)CT/x-ray: multiple patch-like shadows (n=6), ground-glass opacities (n=6), unilateral pneumonia (n=2), bilateral pneumonia (n=6)Oxygen (n=6), mechanical ventilation (n=2), all patients received antivirals (virazole, oseltamivir, interferon), antibiotics (n=5), glucocorticoids (n=5), IVIG (n=4), Chinese medications (n=4)397Sun, KCase seriesChina13NRNRNRNRNRNRNR98Sun, MCase series\*China10.021\
(100%)NRNRNRNR099Tagarro, ACross sectionalSpain413.318\
(44%)Upper respiratory symptoms in 14 (34%), fever (n=11), gastroenteritis or vomiting (n=2)NRNR25 (60%) required hospitalization, 2 received noninvasive ventilation and 1 was intubated4100Tan, XCase seriesChina137.94\
(31%)Respiratory symptoms (n=7), cough (n=6), low fever (n=6), sore throat (n=2), asymptomatic (n=2)LFTs, myocardial enzymes, PCT, coagulation, ferritin were normal, ↑ESR (n=3), CRP level increased (13.2 mg/L)CT: normal (n=7); abnormal: cord-like shadows (n=2), showed ground glass shadows (n=2), had patchy high-density shadow (n=2)\
Lopinavir/ritonavir (n=12), interferon (n=10), arbidol (n=6)0101Tan, YCase seriesChina1073\
(30%)4 patients with fever, 3 with respiratory symptoms, and 1 with vomitingNormal CBC (n=9), ↑WBC and lymphocytes (n=1), ↑AST (n=2), CRP, LDH, and ferritin normal in all patients, mycoplasma+ (n=3)CT: ground-glass opacities (n=5)All patients treated with symptomatic support0102Tang, ACase reportChina1101\
(100%)AsymptomaticCBC:normalCT: normalArbidol, interferon, Chinese medication0103Tong, ZCase series\*China1121\
(100%)NRNRNRNRNR104Turner, DCase seriesIsrael, China, Spain, Italy, Korea, USA, UK, Portugal, France8165\
(63%)Fever (n=3), cough (n=3), myalgia/fatigue (n=4) in children with inflammatory bowel diseaseNRNR5ASA (n=4), infliximab (n=2), thiopurines (n=4), glucocorticoids (n=1)0105Wang, DCase seriesChina317.115\
(48%)Asymptomatic (n=4), fever (n=20), cough (n=14), fatigue and diarrhea (n=3 each), sore throat (n=2), headache/dizziness (n=3), rhinorrhea (n=2), vomiting (n=2)↓Leukocytes and lymphocytes (n=2), ↑CRP (10%), ↑PCT (4%), ↑ESR (19%), ↑transaminases (22%), renal function normalCT lung changes in 14 children, 9 of which showed patchy ground-glass opacitiesInterferon (n=10), Antibiotics (n=6),\
oseltamivir (n=1), 18 were a combination of interferon, oseltamivir, ribavirin, arbidol, and/or lopinavir/ritonavir0106Wang, HCase reportChina181\
(100%)FeverNRCT: left lower lobe ground-glass opacityAntiviral and symptomatic treatmentNR107Wang, JCase reportChina10.051\
(100%)Fever, cough, vomiting, diarrheaOn admission: ↓WBC, ↑monocytes, ↓PltsCT: bilateral pneumonia and bilateral ground-glass opacitiesInterferonNR108Wang, SCase reportChina10.0031\
(100%)AsymptomaticLymphopenia, ↑AST, ↑CK, ↑direct and total bilirubinCT: unilateral ground-glass opacitiesAntibiotic, vitamin K, bolus1109Wang, YCase seriesChina436.9221\
(49%)The most common symptoms were dyspnea (87.5%), fever (62.5%), and cough (62.5%)IL-6, IL-10, D-dimer, total bilirubin, and uric acid were elevated in severe casesAll severe cases had lesions on chest CT; ground-glass opacities (n=24), patchy consolidation (n=9)All severe cases received supplemental oxygen; 5 placed on non-invasive respiratory mode and 3 were intubatedNR110Wei, MCase seriesChina91.12\
(22%)Asymptomatic (n=6), fever (n=4), cough (n=2), rhinorrhea (n=1), sputum production (n=1)NRNRNR0111Wu, PCase reportChina12.831\
(100%)Conjunctivitis and eyelid dermatitisNormal CBC, CRP, CK, liver measurements, ↑CK-MB, ↑LDH, ↓creatinineNormal lung CT and x-rayNRNR112Wu, QCase seriesChina746.844\
(60%)Asymptomatic (40.5%), cough (32.4%) and fever (27.0%)Leukopenia (n=4), lymphopenia (n=4), ↑CRP (n=13), ↑PCT (n=2), ↑ESR (n=5); co-infection (n=26)CT: ground glass opacities (n=9), atypical changes of bronchopneumonia and common viral pneumonia (n=28); normal (n=37)All patients received interferon, Chinese medications, and antivirals; 27 patients received antibiotics1113Wu, ZCross sectionalChina965NRNRNRNRNRNRNR114Xia, WCase seriesChina20NR13\
(63%)Cough (n=13), fever (n=12), diarrhea (n=3), dyspnea (n=2), sore throat (n=1), fatigue (n=1)13 patients with elevated lymphocytes; 2 patients with elevated WBCCT: consolidation (n=10), ground-glass opacities (n=12), shadow (n=4), nodules (n=3)NRNR115Xing, YCase seriesChina3NRNRFever in all patients, gastrointestinal symptoms (n=1)SARS-CoV-2 detectable in stool for 1-3 weeks after negative conversion in throat swabsNRNR0116Xing, YHCase seriesChina34.22\
(67%)Fever (n=3), 1 patient had cough and diarrheaViral RNA remained detectable in stool for longer than 4 weeks, leukocytosis (n=3), ↑Plts (n=2), ↑PCT (n=1), ↑CRP (n=1), ↑LDH (n=1), ↑D-dimer (n=1)CT: unilateral ground glass opacities (n=1), unilateral consolidation (n=1), normal (n=1); CXR: patchy shadows (n=1)Interferon, ribavirin, and Chinese medications were given to all patients0117Xu, YCase seriesChina107.546\
(60%)Fever (n=7), cough (n=5), sore throat (n=4), diarrhea (n=3), rhinorrhea (n=2), asymptomatic (n=1)WBC counts normal, neutropenia (n=4), lymphocytopenia (n=3), lymphocytosis (n=1), ↑PCT (n=5), ↑ESR (n=3),↑CRP (n=3), ↑LDH (n=2), ↑D-dimer (n=1), ↑ferritin (n=1), normal CKNRInterferon (n=10), antibiotics (n=1), IVIG (n=1)NR118Yin, XCase reportChina191\
(100%)Fever; no cough, sore throat, or nauseaLymphopenia, ↑α hydroxybutyrate dehydrogenase, ↑CRP, ↑amyloid, normal PCT and CKCXR: normalAntipyreticNR119Yu, NCase reportChina10.004NRDyspnea; no fever, cough, or diarrheaNRCXR: mild pneumoniaObservation1120Zeng, LCase reportChina10.051\
(100%)Sneezing, vomiting, lethargy, poor feeding↑lymphocytes, ↓neutrophils and procalcitoninCT: bilateral enhanced texture and blurred shadowsNR1121Zeng, LingkongCase seriesChina30.0033\
(100%)Fever (n=2), lethargy (n=2), shortness of breath and cyanosis (n=1), vomiting (n=1)Leukocytosis (n=2), ↑PCT (n=1), ↑CK-MB (n=1), thrombocytopenia (n=1)CT: pneumonia (n=3)Mechanical ventilation (n=1), antibiotics (n=1)3122Zhang, BCase seriesChina468.7529\
(63%)Asymptomatic (n=22), cough (n=15), fever (n=10), rhinorrhea/nasal congestion (n=6), sore throat (n=4), myalgia/fatigue (n=3)No leukopenia or lymphopeniaCXR: ground glass opacity (n=13), mixed ground glass opacity and consolidation (n=4), local patchy shadowing (n=1), consolidation (n=1)Most treated with 1-3 antiviral drugs0123Zhang, B~2~Case seriesChina39.32\
(67%)Asymptomatic (n=2), crying (n=1), fever, cough, and malaise (n=1)PCT normal (n=3), lymphocytosis (n=1), ↑CRP (n=2), ↑CK (n=1), ↑LDH (n=1)CT: normal (n=2); CXR: bilateral pneumonia (n=1)Two hospitalizations for all patients due to persistent SARS-CoV-2 positivity; oseltamivir (n=2), arbidol and lopinavir/ritonavir (n=2), oxygen (n=2), all received Chinese medication0124Zhang, MCase series\*China1151\
(100%)Low-grade fever and myalgiaNRNRNRNR125Zhang, TCase seriesChina37.73\
(100%)Fever (n=2), rhinorrhea (n=2), cough (n=1)Normal electrolytes, liver, and kidney function, normal PCT, LDH, and IL-6; 1 patient with elevated CRP (64.7 mg/L); immunologic profile normal, stool nucleic acid was still positive 10 days after clinical recoveryCT: ground glass opacities (n=2)Interferon, Chinese medications, and vitamin C for all patients, 1 patient received antibiotics0126Zhang, YCase reportChina10.250\
(0%)Fever and sputum productionDecreased neutrophil count; elevated CRP and platelet count, normal PCTNRAmbroxol and aerosolization0127Zhang, ZCase seriesChina40.023\
(75%)Fever (n=2), shortness of breath (n=1), cough (n=1), vomiting (n=1), and 1 asymptomaticNRCT: increased lung markings (n=3)Supportive0128Zhao, WCase seriesChina26.5NRNRNRNRNRNR129Zheng, FCase seriesChina255.114\
(56%)Fever (n=13), cough (n=11), diarrhea (n=3), dyspnea (n=2), vomiting (n=2), abdominal pain (n=2), nasal congestion (n=2)Median WBC, lymphocytes, CRP, CK within normal limits; lymphopenia (n=10), normal renal and coagulation profile (n=23)CT: bilateral patchy shadows/consolidations (n=11), unilateral patchy shadows/consolidations (n=5), normal (n=8)Antiviral therapy (n=12, included interferon, arbidol, oseltamivir, and/or lopinavir/ritonavir), 13 received antibiotics; 2 patients were intubated, and given corticosteroids and IVIG2130Zhou, YCase seriesChina91.584\
(44%)Asymptomatic (n=5), fever (n=4), cough (n=2), rhinorrhea (n=1)normal WBC (n=7), lymphocytosis (n=6), ↑LDH (n=2 of 4 samples), ↑CRP (n=2 of 7 samples)CT: ground-glass opacities (n=7), nodular morphology (n=6)Interferon (n=9), lopinavir (n=6)0131Zhu, LCase seriesChina1095\
(50%)Fever (n=4), cough (n=3), headache (n=2), asymptomatic (n=4)WBC, CRP and PCT normal in all children; ↑ALT (n=2)CT: pneumonia (n=5)Lopinavir/ritonavir (n=4), interferon (n=4), oseltamivir (n=1), antibiotics (n=1), oxygen (n=1), glucocorticoids and IVIG (n=0)0[^2]

Twenty of the publications pertained to the neonatal population and the ages extended from an extremely premature neonate at 26 weeks gestation to 20 years of age. The level of evidence for all of the studies was 5 (1 is highest, 5 is lowest) and the risk of bias scores were between 2 to 7 (1 is lowest, 9 is highest, refer to Appendix 2).

A total of 7780 COVID-19 positive children were included. Fifty six percent of the individuals were male ([Table 2](#tbl0002){ref-type="table"}).Table 2Patient characteristics, exposure status, and hospital stay.Table 2**\# Studies\# PatientsN (%)**Male gender11346402582 (55.6)Mean age (years)11645178.9 ± 0.5Exposure from family member9413601028 (75.6)Travel to/lived-in high-risk area84962689 (71.6)NP/throat SARS-CoV-2 detection89787681 (86.5)Positive fecal viral shedding3132167 (20.9)Positive urine viral shedding22542 (3.7)Length of hospital stay (days)6865211.6 ± 0.3Intensive care unit admission883564116 (3.3)[^3]

The mean age was 8·9 years (SD 0·5) and 75·6% of patients were exposed to a family member who was diagnosed with COVID-19. The most common method for detection of the virus was through nasopharyngeal or throat swab (86·5%). Need for intensive care unit observation or treatment was low (3·3%). Twenty studies (n=655 individuals) reported an underlying medical condition; COVID-19 positive children who were immunosuppressed or had a history of a respiratory or cardiac condition comprised the majority (65·%). Moreover, influenza and Mycoplasma were the most common co-infections (see [Table 3](#tbl0003){ref-type="table"}).Table 3Underlying medical conditions and co-infection.Table 3**\# Studies\# PatientsN (%)Underlying conditions20655233 (35.6)**Immunosuppression71 (30.5)Respiratory49 (21.0)Cardiovascular32 (13.7)Medically complex/congenital malformations25 (10.7)Not reported17 (7.3)Hematologic8 (3.8)Neurologic8 (3.4)Obesity8 (3.4)Prematurity5 (3.4)Endocrine/metabolic5 (2.1)Renal4 (1.7)Gastrointestinal1 (0.5)**Co-infections35118372 (5.6)***Bacterial*Mycoplasma pneumoniae42 (58.3)Enterobacter sepsis2 (2.8)Streptococcus pneumoniae1 (1.4)*Viral*Influenza virus A/B8 (11.1)Respiratory syncytial virus7 (9.7)Cytomegalovirus3 (4.2)Epstein-Barr virus3 (4.2)Adenovirus2 (2.8)Human metapneumovirus2 (2.8)Human parainfluenza virus2 (2.8)

[Table 4](#tbl0004){ref-type="table"} summarizes clinical symptoms and imaging findings in COVID-19 confirmed pediatric patients. No symptoms were described in 456 of 2367 patients (19·3%), while the two most common symptoms were fever (59·1%), and cough (55·9%). While upper respiratory symptoms were characteristic of COVID-19, some patients presented with mild or often overlooked symptoms such as fatigue, abdominal pain, or decreased appetite \[[@bib0014], [@bib0015]--[@bib0016]\]. [Table 4](#tbl0004){ref-type="table"} also summates imaging findings. According to chest x-ray and computed tomography (CT), 23·6% and 18·9% had normal results, respectively. Patchy lesions were observed in 105 of 501 patients on chest radiography and bilateral ground glass opacities were the most frequent CT abnormality.Table 4Clinical symptoms and imagingTable 4**\# Studies\# PatientsN (%)Clinical symptoms**Asymptomatic1192367456 (19.3)Fever11924451446 (59.1)Cough11924451367 (55.9)Rhinorrhea, nasal congestion1192445488 (20.0)Myalgia, fatigue1192445457 (18.7)Sore throat1192445446 (18.2)Shortness of breath, dyspnea1192445287 (11.7)Abdominal pain, diarrhea1192445159 (6.5)Vomiting, nausea1192445131 (5.4)Headache, dizziness1192445104 (4.3)Pharyngeal erythema119244580 (3.3)Decreased oral intake119244542 (1.7)Rash11924456 (0.25)**Chest x-ray findings**Normal49501118 (23.6)Patchy lesions49501105 (21.0)Ground-glass opacity4950130 (6.0)Consolidation4950112 (2.4)**Computed Tomography (CT) findings**Ground-glass opacity671115367 (32.9)Normal671115211 (18.9)Patchy lesions671115117 (10.5)Consolidation67111572 (6.5)

Complete blood counts were the most common laboratory results described (see [Table 5](#tbl0005){ref-type="table"}). Overall, leukocytes were within normal values (7·1 × 10^3^/μL), whereas neutrophils were mildly decreased (44·4%) while lymphocytes were marginally elevated (39·9%). Markers of liver and renal function were normal. Four serum inflammatory markers were above the mean: D-dimer, procalcitonin, creatine kinase, and interleukin-6.Table 5Laboratory values.Table 5**\# Studies\# PatientsMean (SD)Complete blood count**Leukocytes (10^3^/µL)638117.1 (0.3)(normal range 4.0-12.0)Neutrophils (%)4351244.4 (2.7)(normal range 54-62)Lymphocytes (%)5267239.9 (2.0)(normal range 25-33)Hemoglobin (g/dL)3521112.9 (0.9)(normal range 11.5-14.5)Platelets (10^3^/µL)38115272.5 (8.5)(normal range 150-450)**Liver and renal function**Creatinine (mg/dL)274490.3 (0.0)(normal range 0.22-0.59)Aspartate aminotransferase (U/L)3246929.4 (2.2)(normal range 15-50)Alanine aminotransferase (U/L)3565619.5 (1.0)(normal range 5-45)Urea (mg/dL)122274.6 (0.9)(normal range 5-18)**Inflammatory markers**C-reactive protein (mg/L)456439.4 (0.5)(male normal range 0.6-7.9)(female normal range 0.5-10.0)D-dimer (mg/L)\*162850.7 (0.1)(adult normal range \<0.4)Procalcitonin (ng/mL)[†](#tb5fn1){ref-type="table-fn"}292590.25 (0.0)(normal range ≤0.15 ng/mL)Lactate dehydrogenase (U/L)25404276.6 (25.9)(normal range 150-500)Creatine kinase (U/L)25193197.9 (23.1)(adult normal range 5-130)Fibrinogen (mg/dL)\*7179224.2 (1.3)(normal range 220--440)ESR (mm/h)\*713414.1 (3.4)(normal range 0-20)Interleukin-6 (pg/mL)99226.1 (3.7)(normal range ≤1.8)Ferritin (ng/mL)32251.6 (13.2)(normal range 10-60)[^4][^5]

Sixty-six studies (n=614 individuals) provided information regarding treatments. Interferon was the most commonly administered drug (41·0%), followed by empiric antibiotics (20·2%). Of note, glucocorticoids, and intravenous immunoglobulin was used in 4·1% and 3·1% of patients, respectively. Complications we evaluated were rare and only described in 21 studies. There were 7 cases of kidney failure (0·09%), 19 cases of shock (0·24%), and 42 children were intubated (0·54%). More details on treatments provided and complications can be found in [Table 6](#tbl0006){ref-type="table"}.TABLE 6Treatments and complicationsTABLE 6**\# Studies\# PatientsN (%)Treatments**Interferon66614252 (41.0)Antibiotics66614124 (20.2)Remdesivir/unspecified antiviral66614134 (21.8)Herbs/home remedies/other66614126 (20.5)Lopinavir/ritonavir6661471 (11.6)Oseltamivir6661453 (8.6)Hydroxychloroquine6661448 (7.8)Glucocorticoids6661425 (4.1)Intravenous immunoglobulin6661419 (3.1)Arbidol6661416 (2.6)Ribavirin6661413 (2.1)Tocilizumab666149 (1.5)**Complications**Death13177807 (0.09)Mechanical ventilation131778042 (0.54)Shock131778019 (0.24)DIC13177809 (0.12)Kidney failure13177809 (0.12)Cardiac injury13177808 (0.10)MIS-C131778011 (0.14)

Eleven patients (0·14%) met the CDC\'s criteria for MIS-C [@bib0007]. Compared to control (*n*=14), children with severe inflammation were more likely to present with dyspnea (72·7% vs 28·6%), vomiting (45·5% vs. 7·1%), and diarrhea (45·5% vs. 21·4%). White blood cell counts were comparable between the groups; however, patients with MIS-C have significant lymphopenia (11·1% vs. 41·8%). No difference was noted in platelets or liver function markers. Serum lactate dehydrogenase and D-dimer were higher in children with MIS-C (*p*\<0·05, details provided in [Table 7](#tbl0007){ref-type="table"}). Also, patients with MIS-C had lower expression of circulating CD16^+^CD56^+^ natural killer cells. Imaging findings and treatments were comparable in MIS-C and non-MIS-C patients.Table 7Comparison between covid-19 children with and without multisystem inflammatory syndrome in children (MIS-C).Table 7**COVID-19MIS-C**Number of patients1411NAAge, years7.5 (1.8, 13.7)1.1 (0.7, 12.0)0.15Gender, male10 (71.4%)6 (54.5%)0.43**Clinical characteristics**Fever10 (71.4%)10 (90.9%)0.34Cough8 (57.1%)6 (54.5%)1.00Dyspnea4 (28.6%)8 (72.7%)0.04Vomiting1 (7.1%)5 (45.5%)0.02Diarrhea3 (21.4%)5 (45.5%)0.02Underlying medical conditions1 (7.1%)3 (27.3%)0.14**Laboratory parameters**White blood cell count (10^3^/µL)7.8 (4.6, 8.3)9.0 (5.0, 11.3)0.23Neutrophils49.4% (31.4, 65.4)58.9% (55.3, 65)0.25Lymphocytes41.8% (22.4, 53.8)11.1% (5.9, 25.7)\<0.01Hemoglobin (g/dL)12.6 (2.3)12.1 (2.4)0.66Platelets (10^3^/µL)250 (173, 301)193 (107, 251)0.22Aspartate aminotransferase (U/L)23.0 (17.0, 37.0)30.0 (18.8, 36.0)0.96Alanine aminotransferase (U/L)17.0 (11.0, 31.0)26.6 (12.0, 55.0)0.45Creatine kinase (U/L)77 (71, 113)106 (62, 380)0.45Lactate dehydrogenase (U/L)217 (203, 367)459 (380, 609)\<0.01C-reactive protein (mg/L)1.1 (0.5, 9.9)13.3 (1, 57.9)0.07Interleukin-2 (pg/mL)\*2.6 (1.0)1.4 (0.3)0.06Interleukin-4 (pg/mL)\*4.4 (1.5)2.8 (0.8)0.11Interleukin-6 (pg/mL)\*14.3 (4.8, 9.0)118 (4.7, 25.4)0.81Interleukin-10 (pg/mL)\*6.9 (4.8, 9.0)15.1 (4.7, 25)0.56Tumor necrosis alpha (pg/mL)\*4.3 (3.2, 5.4)8.4 (1.4, 4.5)0.46Interferon gamma (pg/mL)\*8.6 (5.9, 15)3.1 (1.5, 21)0.25CD16+CD56+\*11.0% (5.1)4.2% (2.2)0.03CD3+\*72.0% (14.4)60.0% (12.9)0.23CD4+\*29.4% (3.8)34.7% (10.1)0.36D-dimer (mg/L)\*0.3 (0.3, 0.5)40.3 (3.1, 11806)\<0.01Procalcitonin (ng/mL)0.09 (0.09, 0.13)0.11 (0.04, 0.83)0.72**Imaging findings and treatment**Normal chest x-ray7 (50%)0 (0%)0.15Normal lung computed tomography5 (35.7%)0 (0%)0.47Interferon5 (35.7%)5 (45.5%)0.23Oseltamivir3 (21.4%)5 (45.5%)1.00Glucocorticoids2 (14.3%)6 (54.5%)0.13Intravenous immunoglobulin3 (21.4%)5 (45.5%)1.00Virazole3 (21.4%)4 (36.4%)1.00Tocilizumab0 (0%)2 (18.2%)0.49[^6]

Discussion {#sec0008}
==========

Over the last 6 months, there have been over 6·4 million worldwide cases of SARS-CoV-2 infection and our knowledge of the disease and its epidemiologic and clinical characteristics continue to evolve [@bib0004]. However, since it was first reported in Wuhan city in December 2019, most studies have focused on symptomatic adults. In the presence of this rapidly emerging, novel infection, identification of clinical and laboratory characteristics in the pediatric population is essential to guide clinical care, predict disease severity, and determine prognosis. In this context, we performed the largest and most comprehensive systematic review of published studies involving pediatric patients with known COVID-19. Our systematic review summarized the clinical, laboratory and radiologic features of COVID-19 in neonates, children, and adolescents.

Our review also supports the findings by a recent systematic review by Castagnoli et al. [@bib0017] Their study included a total of 1,065 COVID-19 infected children and concluded that, by and large, the prognosis for children was excellent, demonstrated by only one death. Compared to that review and other COVID-19 pediatric systematic reviews, \[[@bib0018], [@bib0019], [@bib0020], [@bib0021]--[@bib0021]\] this manuscript has several key advantages: (1) we summarize 131 studies that includes 7780 children from 26 different countries, (2) this report synthesizes underlying pediatric medical conditions and delineates bacterial and viral coinfections, (3) we quantitatively describe clinical symptoms and imaging findings, (4) herein, we conglomerate the mean and standard deviation of frequently used laboratory analytes in COVID-19 positive children, (5) our report presents antiviral therapies by specific agents, and (6) our systematic review offers a preliminary comparison of patients with/without MIS-C.

Although SARS-CoV-2 infection was first identified in China, the United States has now amassed the highest number of confirmed cases [@bib0018]. Calculations made on June 4th, 2020 from the COVID-19 Dashboard by the Center for

Systems Science and Engineering at Johns Hopkins University indicate that China has 4·5% of total confirmed COVID-19 cases compared to the United States [@bib0004]. As expected, the most common vector for childhood infection is close contact to an affected family member or residing in an area with a high population of cases. Our findings align with the results of an April 2020 report by Dong *et al*, in which there was a clear trend that the disease spread rapidly from a Chinese province to surrounding provinces and cities in children from December to February [@bib0022]. Furthermore, Qiu and colleagues studied 36 pediatric COVID-19 positive patients in which ten patients (28%) were asymptomatic latent cases identified secondary to an adult family member who was infected, symptomatic, or traveled to an endemic area [@bib0023]. This lends concern that children, who may be asymptomatic, may play a role in community transmission of the virus.

Results from this systematic review echo findings describing milder symptoms in pediatric cases of SARS-CoV-2 infection \[[@bib0017],[@bib0021]\]. For instance, the most common clinical manifestations we found were fever (59·1%), cough (55·9%), rhinorrhea (20·0%) and myalgia/fatigue (18·7%). Unlike adults, children rarely progressed to severe upper respiratory symptoms requiring intensive care unit admission \[[@bib0024],[@bib0025]\]. Although transmission rates for SARS-CoV-2 are high, symptoms are less severe than SARS/Middle East Respiratory Syndrome (MERS) infection [@bib0026].

Serum inflammatory markers, specifically D-dimer, procalcitonin, creatine kinase, and interleukin-6, were consistently abnormal in the studies included in this review. Alterations to acute-phase infection-related biomarkers are corroborated in adult case series and meta-analyses \[[@bib0027],[@bib0028]\]. However, we must take caution when interpreting these outcomes and await more robust, longitudinal laboratory analyses. Again, these blood analyses are non-specific and may merely represent a pro-inflammatory state induced by the virus [@bib0026].

In terms of imaging findings, we found that most patients had normal chest x-rays, a finding that is not surprising as most pediatric patients did not present with respiratory symptoms. Paralleling this review, a meta-analysis of CT features for COVID-19, showed that diffuse bilateral ground-glass opacities were the most common finding at all stages of disease \[[@bib0029],[@bib0030]\]. Despite these promising associations, it is important to consider that radiologic manifestations from various pathogens may have a similar impression and should be ruled out. Co-infections with other respiratory illnesses including influenza and mycoplasma were described in 72 patients. As elegantly described by Cox and colleagues, most fatalities from the 1918 influenza outbreak were secondary to bacterial infection [@bib0031]. Thus, future reports should not only describe coinfections but also detail pertinent negatives. At present, our study had a low rate of reporting the infectious workup (26·7) of patients. Illustrating the importance, one of two patients that died in the study by Shekerdemian *et al* was due to gram negative sepsis in a child with comorbidities who developed end organ failure [@bib0032].

Although most children have an uneventful course, a present concern is an inflammatory cascade in pediatric patients with COVID-19 \[[@bib0008],[@bib0009]\]. Clinical presentation includes an unremitting high fever, and includes systemic signs such as rash, conjunctivitis, and/or gastrointestinal symptoms. The case series of eight children from London required respiratory assistance, whether it was oxygen support (*n*=1), noninvasive ventilation (*n*=2) or intubation and mechanical ventilation (*n*=4) [@bib0008]. One patient was so ill that he required mechanical ventilation and extracorporeal membrane oxygenation. In addition, all required vasopressor support and demonstrated elevated levels of ferritin, D-dimers, troponin, procalcitonin, and C-reactive protein (CRP). Additionally, cardiac imaging showed ventricular dysfunction in five children. In another article, Italian investigators describe ten patients with MIS-C. Correspondingly, they describe patients manifesting with fever, diarrhea (*n*=6), and abnormal echocardiograms (*n*=6). Laboratory specifics showed elevated CRP, lymphopenia, thrombocytopenia, and elevated ferritin levels [@bib0009].

We found evidence of MIS-C features in 11 children who also presented with fever (*n*=11), dyspnea (*n*=8), and diarrhea (*n*=6). According to Riphagen and Verdoni, lymphopenia was marked in our cohort of patients, as well as increased levels of lactate dehydrogenase, CRP and D-dimer \[[@bib0008],[@bib0009]\]. Despite low numbers we did observe an interesting lower level of CD16^+^CD56^+^ natural killer (NK) cells in patients with MIS-C. Both lymphopenia and a reduced number/activity of NK cells in adults has correlated with a more severe COVID-19 disease progression \[[@bib0033], [@bib0034], [@bib0035]--[@bib0036]\].

Little is known about the perinatal aspects of COVID-19, and there have been several reported cases of neonatal infection, suggesting a possible perinatal or vertical transmission during pregnancy [@bib0037]. However, in a report by Chen *et al*., all nine neonates born to COVID-19 positive mothers tested negative for the virus after cesarean delivery [@bib0038]. In another study by Zhang *et al.*, 10 neonates from COVID-19 positive mother all tested negative for the infection [@bib0039]. Moreover, this is further supported by analysis of breast milk and placental pathologic specimens from COVID-19 positive mothers, which have returned negative for the virus \[[@bib0040],[@bib0041]\]. Lastly, vertical transmission was not observed with either SARS-CoV-1 or in MERS-CoV;[@bib0041] therefore, it is unlikely that maternal vertical transmission during third trimester occurs, or is likely very rare. However, from the limited data published, we cannot determine the consequences of SARS-CoV-2 infection in early pregnancy and if it can be transmitted to the fetus and hinder organ development, malformations, growth abnormalities, or even lead to premature labor or spontaneous abortions \[[@bib0042],[@bib0043]\]. Also, Dong *et al* communicated an alarming finding in which the proportion of severe and critical cases were higher in neonates when compared to the \>16-year-old age group (10·6% vs. 3·0%) [@bib0044]. As a community, we must stay vigilant, practice social distancing, hand wash frequently, and be especially careful with our children who are at potentially higher risk for critical disease (e.g. multiple comorbidities, weakened immune systems, *etc.*).

There are several limitations to this review. First, many of the included studies were case reports or cases with low patient numbers. Second, the level of evidence for all the studies was low. Next, we unified the laboratory data to mean and standard deviation. There are inherent issues when using averages including the impact of outliers. We did not include suspected cases, which would allow for a direct comparison of symptoms, labs, imaging, and outcome data. Of concern, many of the studies were incomplete and did not include a comprehensive picture of the patients. Future studies should not generalize data ("CBC was normal"), or categorize laboratory values (i.e., number of patients with elevated CRP), or group therapies (i.e., patient received "antiviral therapy"), or display aggregate data between adults and children. If feasible, divide the symptoms, laboratory markers, and imaging characteristics by children vs. adults. A better understanding of COVID-19 requires access to data, even if it is provided in the appendix or supplementary section of the article. In this way, we will be able to identify the best biomarkers that can stratify disease severity and potential short- and long-term outcomes. Another limitation, is that we had a small number of patients that fit the criteria for MIS-C. Reasons for the small number of patients includes a lack of reporting all of the signs, symptoms, and laboratory markers necessary to make the diagnosis (especially duration of fever). Missing information for laboratory markers (D-dimer, interleukins, and CD%) hinders our preliminary findings. Lastly, the literature focusing on COVID-19 is very dynamic and growing rapidly and we expect the rates, especially for MIS-C, of our outcomes to change.
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[^1]: Co-1^st^ author.

[^2]: Abbreviations: ABG-arterial blood gas; ASA-aminosalicylate; ALT- alanine aminotransferase; AST-aspartate aminotransferase; BUN-blood urea nitrogen; BNP-brain natriuretic peptide; CBC-complete blood count; CK-creatine kinase; CPAP-continuous positive airway pressure; Cr-creatinine; CRP-C-reactive protein; CT-computed tomography; CXR-chest radiograph; ESR-erythrocyte sedimentation rate; Hgb-hemoglobin; Ig-immunoglobulin; IL-interleukin; IVIG-intravenous immunoglobulin; LDH-lactate dehydrogenase; LFTs-liver function tests; LUS-lung ultrasound; NK-natural killer cell; NR-not reported; PCT-procalcitonin; Plts-platelets; PT-prothrombin time; PTT-partial thromboplastin time; RSV-respiratory syncytial virus; TNF-tumor necrosis factor. \*One patient met our inclusion, but the publication was a case series.

[^3]: Continuous data presented as Mean ± SD. NP-nasopharyngeal.

[^4]: Given that the mean (SD) in our pediatric population was 8.9 ± 0.5 years we provide the lowest to highest numbers presented in children with a similar age range when possible (data from Nelson Textbook of Pediatrics 2019). \*Gregory\'s Pediatric Anesthesia 2012 5^th^ edition.

[^5]: Mayo clinic laboratories.

[^6]: Data are presented as mean (SD) or median (IQR). Student\'s t test, Wilcoxon rank sum, or Fisher\'s exact was conducted as appropriate. \* denotes limited data was in at least one group (D-dimer in MIS-C=3; Interleukins and CDs had 4 in non-MIS-C group vs. 4-5 in MIS-C).
